Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars
Shanghai Henlius, a clinical-stage pharmaceutical company back by Fosun Pharma, is seeking a listing in Hong Kong. In our previous insight, we have...
905 Views
HLX02: Innovation Could Overtake
The oncology treatment landscape in China is evolving rapidly as the government has prioritized access to innovative drugs to meet this significant...
494 Views
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.1k Views